CHAPEL HILL, NC – (September 30, 2016) – TARGET PharmaSolutions, Inc., a clinical data company focused on real world evidence, is pleased to announce the launch of two disease state communities: TARGET-HCC (Hepatocellular Carcinoma) and TARGET-NASH (Nonalcoholic Steatohepatitis). The TARGET model provides pharmaceutical and biotechnology partners with access to a biorepository linked to validated clinical outcomes, providing unique data and insights compared to typical patient registries. Collaborative partners utilize TARGET-HCC and TARGET-NASH to advance the understanding of real world treatment patterns through resulting clinical data.
TARGET-NASH is led by an academic steering committee chaired by Drs. Arun Sanyal, MD (Virginia Commonwealth University); Ken Cusi, MD (University of Florida), and Brent Tetri (St. Louis University). Dr. Arun Sanyal noted that “TARGET-NASH is critical for the scientific and regulatory community as we prepare for the plethora of new agents for the treatment of NASH. In the immediate term, it will give us a critical understanding of NASH diagnosis and management in the real world – beyond the ivory tower, across multiple populations. In the longer term, it is the perfect platform to have a deep understanding of the safety and effectiveness of these new agents across populations not included or underrepresented in Phase 3 clinical trials.”
TARGET-HCC is led by an academic steering committee chaired by Drs. Adrien Di Bisceglie, MD (Saint Louis University) and Anthony El Khoueiry, MD (University of Southern California). Meg Powell, CEO of TARGET PharmaSolutions, noted that “TARGET-HCC is poised to deliver answers to critical questions about the true natural history and treatment patterns of hepatocellular carcinoma. As new drugs are approved, it will also serve as a platform to have a deeper understanding of the safety and effectiveness of new agents across populations in the real world setting.”
TARGET-NASH’s first patient enrollment occurred August 1, 2016. The company plans on enrolling up to 15,000 patients, at up to 100 sites worldwide. TARGET-HCC’s first patient enrollment is set for Q4 2016. The company plans on enrolling up to 5,000 patients worldwide, at up to 75 sites in the US and Europe.
TARGET PharmaSolutions was formed in February 2015 and currently has four disease communities: TARGET-NASH (nonalcoholic steatohepatitis), TARGET-PBC (primary biliary cholangitis), TARGET-HCC (hepatocellular carcinoma), and TARGET-IBD (inflammatory bowel disease). The TARGET model is based on the success of HCV-TARGET, a case study in Hepatitis C. Formed in 2011 by Drs. Michael Fried, MD (University of North Carolina) and David Nelson, MD (University of Florida), HCV-TARGET has enrolled over 10,000 patients and has generated data that has been used by physicians, payers, and regulatory agencies around the world.
About TARGET PharmaSolutions
TARGET PharmaSolutions is a privately held clinical data company that provides pharmaceutical and biotechnology partners a more efficient way to generate data that can be used to better understand the natural history of diseases, including treatment outcomes in the real-world setting. TARGET PharmaSolutions is based in Chapel Hill, N.C. For more information, visit www.targetpharmasolutions.com
TARGET PharmaSolutions, Inc.